Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 4/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 1/20 | 0.30 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14832663 | 0.82 | POLB (0.40) | KDM4EMEN1KMT2A | |
| SCHEMBL23116158 | 0.76 | KDM4E (0.55) | KDM4EMEN1KMT2AMETRXFP1 | |
| SCHEMBL14832909 | 0.74 | KDM4E (0.53) | KDM4EMEN1KMT2ARXFP1L3MBTL1 | |
| SCHEMBL10996935 | 0.74 | RXFP1 (0.43) | KDM4EMEN1KMT2ARXFP1L3MBTL1 | |
| SCHEMBL23132622 | 0.73 | MAPT (0.31) | OXTRAVPR1A | |
| SCHEMBL1203899 | 0.71 | MEN1 (0.34) | KDM4EMEN1KMT2AMETRXFP1 | |
| SCHEMBL25311269 | 0.71 | KDM4E (0.50) | KDM4EMEN1KMT2A | |
| Bromide SCHEMBL1204335 | 0.70 | MEN1 (0.33) | KDM4EMEN1KMT2AMETRXFP1 | |
| SCHEMBL23116132 | 0.70 | KDM4E (0.41) | KDM4EL3MBTL1CYP1A2 | |
| SCHEMBL26011735 | 0.69 | MET (0.38) | KDM4EMEN1KMT2AMETCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| CN-119371426-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119350320-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240132501-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117756800-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11866439-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220220118-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024930-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| CN-112423760-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731978-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | KDM4E 1179/4885MEN1 3412/4885KMT2A 1247/4885 |
| US-20240132501-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
| US-20220220118-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
| US-20210087197-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
| US-11731976-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator | SCN1A, SCN3A, CACNA1F | KDM4E 1111/4885MEN1 3391/4885KMT2A 1188/4885 |
| US-11866439-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
| US-20210163488-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
| US-20220024930-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | SCN3A, SCN1A, SCN5A | KDM4E 1696/4885MEN1 3118/4885KMT2A 932/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | KDM4E 2324/4885MEN1 2400/4885KMT2A 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.